Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Ivanka Rakita"'
Autor:
Jelena Berendika, Saša Jungić, Biljana Tubić, Gordana Malčić Kecman, Ivanka Rakita, Zdenka Gojković, Milka Vještica, Gordan Nikić, Božana Babić
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 610-615 (2021)
Malignant salivary gland tumors form 11% of all head and neck tumors. Salivary duct carcinoma (SDC) of the parotid gland is an uncommon and highly aggressive tumor accounting for 2% of all salivary gland malignancies. The fourth edition of the WHO Cl
Externí odkaz:
https://doaj.org/article/7dfa51728e4e49a1b8aaf8afff4ca764
Autor:
Semir Bešlija, Zdenka Gojković, Timur Cerić, Alma Mekić Abazović, Inga Marijanović, Semir Vranić, Jasminka Mustedanagić–Mujanović, Faruk Skenderi, Ivanka Rakita, Aleksandar Guzijan, Dijana Koprić, Alen Humačkić, Danijela Trokić, Jasmina Alidžanović, Alma Efendić, Ibrahim Šišić, Harun Drljević, Vanesa Bešlagić, Božana Babić, Azra Pašić, Anela Ramić, Dijana Mikić, Zlatko Guzin, Dragana Karan, Teo Buhovac, Dragana Miletić, Senad Šečić, Azra Đozić Šahmić, Lejla Mujbegović, Alisa Kubura, Mensura Burina, Nenad Lalović, Nikolina Dukić, Jelena Vladičić Mašić, Mirjana Ćuk, Rajna Stanušić
Publikováno v:
Biomolecules & Biomedicine, Vol 21, Iss 2 (2021)
The HERe2Cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and
Externí odkaz:
https://doaj.org/article/4233acf6fd3e404d8077ba8f24c2e083
Autor:
Dejan Djokanovic, Zdenka Gojkovic, Sasa Jungic, Jelena Berendika, Radoslav Gajanin, Biljana Tubić, Ivanka Rakita, Milka Vjestica
Publikováno v:
Vojnosanitetski pregled. 79:796-804
Background/Aim. Standard treatment options for the first-line treatment of metastatic colorectal carcinoma (mCRC) are 5-fluorouracil, folinic acid, oxaliplatin (FOL-FOX4)/capecitabine (CapOx), plus bevacizumab (bev) and 5-fluorouracil, folinic acid a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::249d0f7340b0a608f581aeffe3a776e4
https://doi.org/10.2298/vsp200924053j
https://doi.org/10.2298/vsp200924053j
Autor:
Jelena Berendika, Saša Jungić, Biljana Tubić, Ivanka Rakita, Milka Vještica, Dejan Đokanović, Zdenka Gojković, Nikolina Mirčeta, Sanja Petković, Vanda Marković-Peković
Publikováno v:
Scripta Medica. 53:29-35
Background / Aim: Up until ten years ago stage four melanoma was considered a disease with extremely poor prognosis. Standard therapy during this period of time was dacarbazine chemotherapy. Patients with better performance status were treated with i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::129179c955b47926731c51aa87b6e68f
https://doi.org/10.5937/scriptamed53-35184
https://doi.org/10.5937/scriptamed53-35184
Publikováno v:
Vojnosanitetski Pregled, Vol 74, Iss 3, Pp 249-255 (2017)
Background/Aim. The efficacy and safety of bevacizumab (BEV) in combination with capecitabin and irinotecan in first-line therapy for patients with metastatic colorectal cancer (mCRC) were studied. In order to improve safety and efficacy of chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7106ae008e6c435adeb0d9ecc95e6f06
http://www.doiserbia.nb.rs/img/doi/0042-8450/2017/0042-84501600173J.pdf
http://www.doiserbia.nb.rs/img/doi/0042-8450/2017/0042-84501600173J.pdf
Autor:
Sasa Jungic, Zdenka Gojkovic, Ivanka Rakita, Dejan Djokanovic, Tamara Visekruna, Gordan Nikic, Milka Vjestica, Olja Jovic-Djokanovic, Jelena Berendika, Zoran Mavija
Publikováno v:
Vojnosanitetski Pregled, Vol 77, Iss 11, Pp 1235-1236 (2020)
nema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f03fe0f7eba62ce093173d8d6b69705
https://doi.org/10.2298/vsp201016114g
https://doi.org/10.2298/vsp201016114g
Autor:
Branislava Jakovljevic, Zdenka Gojkovic, Ivanka Rakita, Sasa Jungic, Marina Štrbac, Dejan Đokanović, Siniša Maksimović, Milka Vjestica, Radmila Raseta, Živko Vranješ
Publikováno v:
SCRIPTA MEDICA. 49
Introduction: The introduction of BRAF inhibitor vemurafenib significantly improvedoverall survival (OS) in metastatic melanoma patients.Aim of the Study: The purpose of this study was to determine OS and progressionfree survival (PFS) in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2ab89d2ed0379a1ee684484ed8154e2
https://doi.org/10.7251/scmed1802126g
https://doi.org/10.7251/scmed1802126g
Autor:
Dalibor Grahovac, Aleksandar Guzijan, Ivanka Rakita, Zdenka Gojkovic, Zoran Aleksić, Brano Topic, Milka Vjestica, Predrag Dasic, Marina Vižin
Publikováno v:
Биомедицинска истраживања. 4:1-7
Uvod. Histoloski gradus (HG), koji oznacava zrelost tumora, i nuklearni gradus (NG), koji predstavlja nuklearnu morfometriju, važni su prognosticki faktori karcinoma dojke. Sa progresijom tumora povezan je i vaskularni endotelijalni faktor rasta (VE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b64a0019b28cb921bb3a7e2dbc2d8ea8
https://doi.org/10.7251/bii1302001g
https://doi.org/10.7251/bii1302001g
Autor:
Radoslav Gajanin, Zeljka Cvijetic, Sasa Jungic, Branislava Jakovljevic, Darjana Jovanovic, Ivanka Rakita, Zdenka Gojkovic
Publikováno v:
Archive of Oncology, Vol 14, Iss 3-4, Pp 118-121 (2006)
Background: Breast carcinoma recurrence appears in 5%-30% of cases, after the completion of breast cancer treatment. Recurrence appears on thoracic wall (chest wall), on the skin, on the breast tissue remaining after the surgery, equal sided axillary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8d7d0fb9ffed434753c39b5f1625471
https://doi.org/10.2298/aoo0604118g
https://doi.org/10.2298/aoo0604118g
Publikováno v:
Scripta Medica. 35:85-89
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c308a6e53daebed3e53b5393246f1aa2
https://doi.org/10.5937/scrimed0402085j
https://doi.org/10.5937/scrimed0402085j